Core Viewpoint - Algernon Health Inc. is conducting a non-brokered private placement to raise gross proceeds of $500,000 through the issuance of units priced at $0.07 each, aimed at advancing its Alzheimer's Disease program and other operational needs [1][5]. Group 1: Offering Details - The offering consists of units, each comprising one Class A common share and one-half common share purchase warrant, with a full warrant allowing the purchase of one common share at an exercise price of $0.15 for 12 months [2]. - The exercise price of the common warrants will increase to $0.25 after the first anniversary and to $0.50 after the second anniversary of the issuance date [2][3]. - The offering is expected to close in tranches by November 30, 2025, with potential cash finder's fees of up to 8% of the proceeds [4]. Group 2: Use of Proceeds - Proceeds from the offering will be utilized to advance the company's Alzheimer's Disease program, cover general and administrative expenses, and for working capital purposes [5]. Group 3: Share Structure and Securities - The company has converted 1,268,334 subscription receipts into Series 1 preferred shares and issued additional preferred shares and warrants related to previous placements and acquisitions [7]. - The Series 1 preferred shares carry a 10% annual dividend and are convertible into ten Class A common shares, with voting rights [9]. Group 4: Company Overview - Algernon Health focuses on brain-specific PET scanning services for early-stage detection of Alzheimer's and other neurological conditions, and is advancing a psychedelic program for recovery from stroke and traumatic brain injury [10].

VANCOUVER, British Columbia, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company announces the voting results at its annual and special meeting of shareholders held earlier today (the "Meeting") including an ordinary resolution (the “Resolution”) to approve an alteration to the Company’s authorized share structure and Articles, to include an unlimited number of Preferred Shares, of which an ...